| abstract |
The application relates to a method of treating a subject suffering from Crohn's disease, where the method includes regularly administering to said subject an amount of laquinimod or a pharmaceutically acceptable salt thereof effective for treating the subject, where the subject had a level of C-reactive protein above 5 mg / L before the introduction of laquinimod. In addition, the present application relates to the use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease, where the subject had a level of C-reactive protein higher than 5 mg / l prior to the administration of laquinimod. |